|Bid||17.80 x 2000|
|Ask||17.95 x 4700|
|Day's range||17.95 - 18.00|
|52-week range||9.30 - 18.75|
|PE ratio (TTM)||N/A|
|Earnings date||6 Mar 2018 - 12 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||21.67|
Last year's FDA approval of Agios' (AGIO) only marketed drug Idhifa and its rapid progress on a robust pipeline during the period drive the share price consistently.
NEW YORK, Jan. 18, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), Hersha Hospitality Trust (NYSE:HT), Archrock, Inc. (NYSE:AROC), SJW Corporation (NYSE:SJW), Franklin Financial Network, Inc. (NYSE:FSB), and Digi International Inc. (NASDAQ:DGII), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Regulatory approvals of some key pipeline candidates along with the strong performance of products like Victoza have contributed to a rally in Novo Nordisk's (NVO) shares.
Endo International (ENDP) lost 35% in the past year mired by controversy related to Opana ER and weaknesses in both the businesses.
The FDA panel votes against the approval of Aradigm's (ARDM) Linhaliq for treatment of non-cystic fibrosis bronchiectasis. A response from the regulatory agency is expected on Jan 26, 2018.
Endo (ENDP) announced that it received a subpoena from the Florida authorities in connection with products related to opioid misuse.
Adamas (ADMS) shares climb on the commercial launch of Gocovri in the United States for treating dyskinesia in patients with Parkinson's disease. This is the first FDA approved drug for the ailment.
Acorda (ACOR) announces preliminary sales numbers of its key multiple sclerosis drug, Ampyra, for Q4. The company's net sales expectations are higher year over year.
Mallinckrodt's (MNK) strategy to streamline its business to evolve as a top-performing specialty pharmaceutical company has led the company to enter into an agreement to sell Recothrom and Preveleak to Baxter.
Chris and Hugh Hempel, parents of twin girls with an extremely rare and fatal genetic disease, are suing the rare disease therapy accelerator Cydan and the biotech companies Vtesse and Sucampo Pharmaceuticals for alleged breach of contract, unjust enrichment, and misappropriation of trade secrets.
Emergent (EBS) initiates a phase II dose-ranging trial to evaluate the safety, pharmacokinetics and clinical benefit of its investigational FLU-IGIV to treat influenza virus infection.
Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.
Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.
Merck's (MRK) anti-PD-1 therapy, Keytruda, gains approval in Japan for previously-treated patients with bladder cancer. Keytruda can now be indicated for four types of cancer in Japan.
The following statement is being issued by Levi & Korsinsky, LLP:
Inovio (INO) entered into an amended agreement with ApolloBio Corporation and grants ApolloBio the exclusive right to develop and commercialize VGX-3100 within Greater China.
The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Aradigm and Sucampo Pharmaceuticals
Valeant (VRX) and Pershing Square decided to resolve the claims of the long standing Allergan lawsuit for $290 million. Valeant will now pay 33% of the costs, down from the previous agreement of 60%.
2017 saw the FDA approving 46 novel drugs as well as path-breaking treatments like Novartis's (NVS) Kymriah and Gilead's Yescarta. Here is a look at three companies expecting a decision this January.
Former United States Securities and Exchange Commission attorney Willie Briscoe is investigating potential claims against the Board of Directors of Sucampo Pharmaceuticals, Inc. concerning the sale to Mallinckrodt plc.